Publication
Article
Pharmaceutical Technology
Author(s):
A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?
Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook March 2021 eBook.
Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4-5
When referring to this article, please cite it as A. Shanley, “Can FDA Reinvent Inspections,” Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.